PROOF, Adiga Collaborate on Biomarkers for Allergy Vaccines | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Canada's Centre of Excellence for the Prevention of Organ Failure (PROOF) and Adiga Life Sciences announced today a collaboration to identify proteomic and genomic biomarkers for monitoring the effectiveness of allergy vaccines.

Knowledge gained from the project is expected to lead to a better understanding of how such vaccines work, which will then be used to guide development of molecular tests for diagnosing and managing allergic rhinitis, PROOF said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.